Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer

Triple-negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States, lacks targeted therapeutic options, and is associated with a 40–80% risk of recurrence. Thus, identifying actionable targets in treatment-naïve and chemoresistant TNBC is a critical unmet medical ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Reid T., Redwood, Abena, Liu, Xuan, Guo, Lei, Cai, Shirong, Zhou, Xinhui, Tu, Yizheng, Zhang, Xiaomei, Qi, Yuan, Jiang, Yan, Echeverria, Gloria, Feng, Ningping, Ma, XiaoYan, Giuliani, Virginia, Marszalek, Joseph R., Heffernan, Timothy P., Vellano, Christopher P., White, Jason B., Stephan, Clifford, Davies, Peter J., Moulder, Stacy, Symmans, W. Fraser, Chang, Jeffrey T., Piwnica-Worms, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578025/
https://www.ncbi.nlm.nih.gov/pubmed/33087803
http://dx.doi.org/10.1038/s41598-020-74882-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578025/
https://www.ncbi.nlm.nih.gov/pubmed/33087803
http://dx.doi.org/10.1038/s41598-020-74882-4

Ejemplares similares